Cargando…

Pathological Insight into 5-HT(2B) Receptor Activation in Fibrosing Interstitial Lung Diseases

Interstitial lung disease (ILD) encompasses a heterogeneous group of more than 200 conditions, of which primarily idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, hypersensitivity pneumonitis, ILD associated with autoimmune diseases and sarcoidosis may present a pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Löfdahl, Anna, Tornling, Göran, Wigén, Jenny, Larsson-Callerfelt, Anna-Karin, Wenglén, Christina, Westergren-Thorsson, Gunilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796180/ https://www.ncbi.nlm.nih.gov/pubmed/33379351 http://dx.doi.org/10.3390/ijms22010225

Ejemplares similares

Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT(2B) receptor antagonists in vitro – a potential pathway affecting proliferation
por: Löfdahl, Anna, et al.
Publicado: (2018)

5‐HT (2B) receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo
por: Löfdahl, Anna, et al.
Publicado: (2016)

Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity
por: Wigén, Jenny, et al.
Publicado: (2020)

Effects of hypoxia on bronchial and alveolar epithelial cells linked to pathogenesis in chronic lung disorders
por: Berggren-Nylund, Rebecca, et al.
Publicado: (2023)

Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts
por: Larsson-Callerfelt, Anna-Karin, et al.
Publicado: (2013)

A tunable physiomimetic stretch system evaluated with precision cut lung slices and recellularized human lung scaffolds
por: Rosmark, Oskar, et al.
Publicado: (2022)

Harnessing the ECM Microenvironment to Ameliorate Mesenchymal Stromal Cell-Based Therapy in Chronic Lung Diseases
por: Elowsson Rendin, Linda, et al.
Publicado: (2021)

Alveolar epithelial cells are competent producers of interstitial extracellular matrix with disease relevant plasticity in a human in vitro 3D model
por: Rosmark, Oskar, et al.
Publicado: (2023)

Mast cells and mast cell tryptase enhance migration of human lung fibroblasts through protease-activated receptor 2
por: Bagher, Mariam, et al.
Publicado: (2018)

Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study
por: Hamberg, Viggo, et al.
Publicado: (2023)

Pressurized carbon dioxide as a potential tool for decellularization of pulmonary arteries for transplant purposes
por: Gil-Ramírez, Alicia, et al.
Publicado: (2020)

Quantifying extracellular matrix turnover in human lung scaffold cultures
por: Rosmark, Oskar, et al.
Publicado: (2018)

Versican in inflammation and tissue remodeling: The impact on lung disorders
por: Andersson-Sjöland, Annika, et al.
Publicado: (2015)

Matrisome Properties of Scaffolds Direct Fibroblasts in Idiopathic Pulmonary Fibrosis
por: Elowsson Rendin, Linda, et al.
Publicado: (2019)

CD105(+)CD90(+)CD13(+) identifies a clonogenic subset of adventitial lung fibroblasts
por: Kadefors, Måns, et al.
Publicado: (2021)

Crosstalk between Mast Cells and Lung Fibroblasts Is Modified by Alveolar Extracellular Matrix and Influences Epithelial Migration
por: Bagher, Mariam, et al.
Publicado: (2021)

Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis
por: Kalafatis, Dimitrios, et al.
Publicado: (2021)

Silver Nanoparticles Alter Cell Viability Ex Vivo and in Vitro and Induce Proinflammatory Effects in Human Lung Fibroblasts
por: Löfdahl, Anna, et al.
Publicado: (2020)

Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Altered fibroblast proteoglycan production in COPD
por: Hallgren, Oskar, et al.
Publicado: (2010)

The Burden of Progressive-Fibrosing Interstitial Lung Diseases
por: Cottin, Vincent, et al.
Publicado: (2022)

Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021)

Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019)

The natural history of progressive fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2019)

The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020)

Management and support of patients with fibrosing interstitial lung diseases
por: Barbera, Tyonn, et al.
Publicado: (2021)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease
por: Abu Qubo, Ahmad, et al.
Publicado: (2022)

Acute exacerbations of progressive-fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2018)

Role of imaging in progressive-fibrosing interstitial lung diseases
por: Walsh, Simon L.F., et al.
Publicado: (2018)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Burden of illness in progressive fibrosing interstitial lung disease
por: Singer, David, et al.
Publicado: (2022)

Ciliated (FOXJ1(+)) Cells Display Reduced Ferritin Light Chain in the Airways of Idiopathic Pulmonary Fibrosis Patients
por: Wijk, Sofia C., et al.
Publicado: (2022)

Activated MC(TC )mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis
por: Andersson, Cecilia K, et al.
Publicado: (2011)

Diffuse pulmonary ossification associated with fibrosing interstitial lung disease
por: Alami, Badreeddine, et al.
Publicado: (2019)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
por: Kwon, Byoung Soo, et al.
Publicado: (2021)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2auaot2bt86ilvrc1r3h7dgbs7